[144] Tango Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Tango Therapeutics, Inc. Form 144 notice shows a proposed sale of 86,459 shares of common stock to be executed through BTIG, LLC on 09/08/2025 on the NASDAQ GM, with an aggregate market value listed as $608,628.13. The filing records that these shares were acquired on 03/23/2017 as a pre-IPO investment and that payment was made by wire. The document also discloses sales by Third Rock Ventures IV, L.P. totaling 2,045,100 shares sold on 08/19/2025, 08/22/2025, and 09/05/2025 with combined gross proceeds of $8,718,970.24. The filer attests there is no undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Notice shows insider-related and institutional selling, but no operational details to assess company performance.

The Form 144 documents a proposed sale of 86,459 shares and recent institutional dispositions totaling 2,045,100 shares generating about $8.72 million. These sales are clearly disclosed and executed through an established broker. The filing provides transaction dates, acquisition origin (pre-IPO), and payment method, but contains no company operational or financial metrics. For valuation or liquidity implications, market context and share-price history would be required, which are not included here.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure of proposed sale and recent aggregated sales; no governance red flags in this notice alone.

The filing meets Rule 144 disclosure elements: seller identity, class, amount, acquisition date and nature, broker details, and attestations. It confirms pre-IPO acquisition and wire payment. The document does not report any material undisclosed information per the signer’s representation. This notice alone does not indicate governance issues, though repeated large insider or affiliate sales could warrant monitoring when combined with other disclosures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	86459	608628.13	111260247	09/08/2025	NASDAQ GM

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/23/2017	Pre-IPO investment	Tango Therapeutics Inc			86459	03/23/2017	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Third Rock Ventures IV, L.P. 201 BROOKLINE AVENUE Suite 1401 BOSTON MA 02215	Common	08/19/2025	1100000	2115358.00
Third Rock Ventures IV, L.P. 201 BROOKLINE AVENUE Suite 1401 BOSTON MA 02215	Common	08/22/2025	302194	2103270.24
Third Rock Ventures IV, L.P. 201 BROOKLINE AVENUE, suite 1401 BOSTON MA 02215	Common	09/05/2025	642906	4500342.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Tango Therapeutics (TNGX) disclose?

The Form 144 discloses a proposed sale of 86,459 shares to be sold through BTIG, LLC on 09/08/2025, and prior sales by Third Rock Ventures totaling 2,045,100 shares with gross proceeds of $8,718,970.24.

When were the shares being proposed for sale by the filer originally acquired?

The shares subject to this Form 144 were acquired on 03/23/2017 as a pre-IPO investment, and payment was made by wire.

Through which broker will the proposed TNGX sale be executed?

The proposed sale lists BTIG, LLC, 350 Bush Street, 9th Floor, San Francisco, CA as the broker.

How many shares does Tango Therapeutics have outstanding according to the filing?

The filing reports 111,260,247 shares outstanding for the class of common stock listed.

Did the filer represent any undisclosed material information about Tango Therapeutics?

By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.